Patents by Inventor Larry D. Bratton

Larry D. Bratton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7244763
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: July 17, 2007
    Assignee: Warner Lambert Company LLC
    Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 7067538
    Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: June 27, 2006
    Assignee: Warner-Lambert Company, LLC
    Inventors: Larry D. Bratton, Alexander J. Bridges, David T. Connor, Steven R. Miller, Yuntao Song, Kuai-Lin Sun, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 6964983
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: November 15, 2005
    Assignee: Warner-Lambert Company, LLC
    Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 6939875
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: September 6, 2005
    Assignee: Warner-Lambert Company
    Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 6875780
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: April 5, 2005
    Assignee: Warner-Lambert Company
    Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
  • Publication number: 20040209936
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 21, 2004
    Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
  • Publication number: 20030225158
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Application
    Filed: January 22, 2003
    Publication date: December 4, 2003
    Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 6329392
    Abstract: The present invention relates to novel substituted piperidine derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic diseases including: seasonal rhinitis, allergic rhinitis, and sinusitis.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: December 11, 2001
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Timothy P. Burkholder, Larry D. Bratton, Elizabeth M. Kudlacz, George P. Maynard, John M. Kane, Braulio Santiago
  • Patent number: 6297259
    Abstract: The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: October 2, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: George P. Maynard, John M. Kane, Larry D. Bratton, Elizabeth M. Kudlacz
  • Patent number: 6211199
    Abstract: The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: April 3, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: John M. Kane, George D. Maynard, Timothy P. Burkholder, Larry D. Bratton, Christopher R. Dalton, Braulio Santiago, Elizabeth M. Kudlacz
  • Patent number: 6194406
    Abstract: The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: February 27, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: John M. Kane, George D. Maynard, Timothy P. Burkholder, Larry D. Bratton, Christopher R. Dalton, Elizabeth M. Kudlacz, Braulio Santiago
  • Patent number: 5998439
    Abstract: The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: December 7, 1999
    Assignee: Hoescht Marion Roussel, Inc.
    Inventors: George P. Maynard, John M. Kane, Larry D. Bratton, Elizabeth M. Kudlacz
  • Patent number: 5932571
    Abstract: The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)?1,4!diazepan-1-yl)-2-(aryl)butyl)b enzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: August 3, 1999
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: George D. Maynard, John M. Kane, Christopher R. Dalton, Braulio Santiago, Elizabeth M. Kudlacz, Larry D. Bratton
  • Patent number: 5730922
    Abstract: A laminate has at least two layers, at least one of which comprises a polymer having more than one perfluorocyclobutane group. Such polymers impart qualities of environmental or protection, chemical and solvent resistance, hydrolytic stability, lubricity, low dielectric, hydrostatic stability, weatherability, flame resistance, chemical resistance, hydrolytic stability, lubricity, environmental protection, scratch resistance, solvent resistance, surface passivation, water repellancy, lower surface refractive index, lower surface coefficient of friction, fluid barrier properties, oil repellancy, thermal stability, and/or reduced moisture pick-up. Additionally, the coatings are optically clear, easy to apply either neat, in a solvent or otherwise, have relatively low cure temperatures for their temperature resistance, and exhibit insulating and planarizing capabilities.
    Type: Grant
    Filed: July 12, 1996
    Date of Patent: March 24, 1998
    Assignee: The Dow Chemical Company
    Inventors: David A. Babb, W. Frank Richey, Katherine Clement, Edward R. Peterson, Alvin P. Kennedy, Zdravko Jezic, Larry D. Bratton, Eckel Lan, Donald J. Perettie
  • Patent number: 5409777
    Abstract: A laminate has at least two layers, at least one of which comprises a polymer having more than one perfluorocyclobutane group. Such polymers impart qualities of enviornmental or protection, chemical and solvent resistance, hydrolytic stability, lubricity, low dielectric, hydrostatic stability, weatherability, flame resistance, chemical resistance, hydrolytic stability, lubricity, environmental protection, scratch resistance, solvent resistance, surface passivation, water repellancy, lower surface refractive index, lower surface coefficient of friction, fluid barrier properties, oil repellancy, thermal stability, and/or reduced moisture pick-up. Additionally, the coatings are optically clear, easy to apply either neat, in a solvent or otherwise, have relatively low cure temperatures for their temperature resistance, and exhibit insulating and planarizing capabilities.
    Type: Grant
    Filed: June 15, 1993
    Date of Patent: April 25, 1995
    Assignee: The Dow Chemical Company
    Inventors: Alvin P. Kennedy, Larry D. Bratton, Zdravko Jezic, Eckel R. Lane, Donald J. Perettie, W. Frank Richey, David B. Babb, Katherine S. Clement
  • Patent number: 5246782
    Abstract: A laminate has at least two layers, at least one of which comprises a polymer having more than one perfluorocyclobutane group. Such polymers impart qualities of enviornmental or protection, chemical and solvent resistance, hydrolytic stability, lubricity, low dielectric, hydrostatic stability, weatherability, flame resistance, chemical resistance, hydrolytic stability, lubricity, environmental protection, scratch resistance, solvent resistance, surface passivation, water repellancy, lower surface refractive index, lower surface coefficient of friction, fluid barrier properties, oil repellancy, thermal stability, and/or reduced moisture pick-up. Additionally, the coatings are optically clear, easy to apply either neat, in a solvent or otherwise, have relatively low cure temperatures for their temperature resistance, and exhibit insulating and planarizing capabilities.
    Type: Grant
    Filed: December 10, 1990
    Date of Patent: September 21, 1993
    Assignee: The Dow Chemical Company
    Inventors: Alvin P. Kennedy, Larry D. Bratton, Zdravko Jezie, Eckel R. Lane, Donald J. Perettie, W. Frank Richey, David A. Babb, Katherine S. Clement
  • Patent number: RE39916
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: November 6, 2007
    Assignee: Warner Lambert Company
    Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst